Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | MLYCD | O95822 | 2/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24429320 | 0.91 | LDLR (0.53) | CHRM4NPC1RAB9AACHEMLYCD | |
| SCHEMBL8395193 | 0.86 | SMN1; SMN2 (0.68) | NPC1RAB9AACHEEPHX2SMN1; SMN2 | |
| SCHEMBL8396478 | 0.86 | SMN1; SMN2 (0.68) | NPC1RAB9AACHEEPHX2SMN1; SMN2 | |
| SCHEMBL8393679 | 0.85 | ACHE (0.66) | NPC1RAB9AACHEEPHX2SMN1; SMN2 | |
| SCHEMBL10724023 | 0.85 | LDLR (0.62) | NPC1RAB9AACHEMLYCDSMN1; SMN2 | |
| SCHEMBL17117316 | 0.83 | EPHX1 (0.69) | NPC1RAB9AEPHX2SMN1; SMN2 | |
| SCHEMBL22919723 | 0.82 | CXCR4 (0.61) | NPC1RAB9AACHEMLYCDSMN1; SMN2 | |
| SCHEMBL8391438 | 0.82 | ACHE (0.66) | CHRM4NPC1RAB9AACHESMN1; SMN2 | |
| SCHEMBL8391413 | 0.81 | SMN1; SMN2 (0.64) | NPC1RAB9AACHEHDAC8EPHX2 | |
| SCHEMBL8393231 | 0.81 | SMN1; SMN2 (0.64) | NPC1RAB9AACHEHDAC8EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153722-A1 | CDK2/5 DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153722-A1 | CDK2/5 DEGRADERS AND USES THEREOF | CDK2, CDK5, CDK5R1 | CHRM4 4632/4885NPC1 3969/4885RAB9A 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.